Accenture (ACN)

Accenture's stock has pulled back from its recent highs but remains well above its longer-term averages. Analysts are split and lean cautious: 10 of 27 rate the stock buy or strong buy, 17 rate it hold, and none rate it sell. Its median 12-month target of $232.50 sits below the current price, which makes the next few sessions a test of whether the rally can hold near the 20-day average.

Analyst activity in October was mostly steady, with one notable change. Baird downgraded the stock to Neutral from Outperform on October 21, 2026. Wells Fargo kept its Equal-Weight rating on October 26, TD Cowen and Susquehanna kept their Hold and Neutral ratings on October 15, Mizuho kept its Outperform rating on October 6, and Goldman Sachs kept its Buy rating on October 2. Three months ago 14 of 27 ratings were buy, against 10 of 27 today, so the balance has moved toward hold.

At a trailing P/E of 18.71, the stock trades at a 46.7% discount to the sector median P/E of 35.1. Its price-to-sales ratio of 2.00 compares with a sector median of 7.6. Profitability is the offset, with a 10.86% net margin, a 16.42% operating margin, a 26.03% return on equity against a sector median of 13.4%, and a debt-to-equity ratio of 0.40.

The stock has beaten the EPS estimate in all eight of the last eight reports, with the October 1, 2026 report at $3.29 against a $3.18 estimate, a 3.46% beat. The share price rose 15.78% in the first session after that report. Five of the eight beats were followed by a lower share price, so an EPS beat has not reliably led to a rise.

Over the last 18 months insiders sold $22.1M of stock across 31 sales and bought $3.2M across two open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than open-market buying, and it is not clear whether these particular sales were planned.

The base case is that the stock trades in a range set by its moving averages while analysts digest the recent rating changes. The price is above the 20-day EMA at $246.01, the 50-day SMA at $214.30 and the 200-day SMA at $190.49, and the 50-day average remains well above the 200-day average, which keeps the longer trend intact. Upside would need the price to reclaim the $291.09 high, which would require growth to improve from the latest quarter's 5.59% gain. Downside pressure would build if the price closes below the 20-day EMA and the stock moves toward the 50-day SMA. Analysts' median target of $232.50 sits below the current price, and the highest target of $300.00 is the bull case on the Street. Analysts expect EPS to grow 5.0% this fiscal year and 8.4% next year, so earnings growth is the main support for any move higher from here.

Support sits first at the 20-day EMA of $246.01, which the price is currently just above. Below that is the 50-day SMA at $214.30, a level the stock would reach only after a clear loss of the short-term average. The 200-day SMA at $190.49 is the next support further down, followed by the 52-week low of $118.15. Resistance sits at the 52-week high of $291.09, the nearest level above the price. A move through that high would be a new 52-week high.